Your browser doesn't support javascript.
loading
Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.
Hanke, Nina; Kunz, Claudia; Thiemann, Meinolf; Fricke, Harald; Lehr, Thorsten.
Affiliation
  • Hanke N; Clinical Pharmacy, Saarland University, 66123 Saarbrücken, Germany. n.hanke@mx.uni-saarland.de.
  • Kunz C; Apogenix AG, 69120 Heidelberg, Germany. claudiakunz@gmx.de.
  • Thiemann M; Apogenix AG, 69120 Heidelberg, Germany. meinolf.thiemann@apogenix.com.
  • Fricke H; Apogenix AG, 69120 Heidelberg, Germany. harald.fricke@me.com.
  • Lehr T; Clinical Pharmacy, Saarland University, 66123 Saarbrücken, Germany. thorsten.lehr@mx.uni-saarland.de.
Pharmaceutics ; 11(4)2019 Apr 01.
Article in En | MEDLINE | ID: mdl-30939793
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies Language: En Journal: Pharmaceutics Year: 2019 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies Language: En Journal: Pharmaceutics Year: 2019 Document type: Article Affiliation country: